We are developing a series of drugs to improve overall survival in acute myeloid leukemia patients

MaaT013 – Steroid-Refractory Acute Graft-Versus-Host Disease (SRaGvHD) program – enema


Objectives Status
› Evaluation of Complete Response (CR) or Very Good Partial Response (VGPR) of Steroid Refractory, Gastrointestinal, Acute Graft-Versus-Host Disease (SRaGvHD) treated with MaaT013 (pooled donors) › First Patient In (FPI): august 2018
3 Positive DSMBs (first 15 Patients) –> Study continuing without amendments
Readout expected in 1Q 2021

MaaT 033 – Oral Form – improvement of overall survival in hematological patients


Objectives Status
 Optimal dose
Phase 1 started in November 2020 : see Press Release here

What are Hematological Malignancies?

They are rare cancers (also know as blood cancers) that affect the blood, bone marrow, lymph and lymphatic system. These cancers are subdivided according to which type of blood cells are affected:
Lymphoblastic or lymphocytic: a malignancy in the lymphoid lineage that produces white blood cells such as T and B lymphocytes. Examples include acute lymphoblastic leukemia, chronic lymphocytic leukemia, Hodgkin’s and Non-Hodgkin lymphomas and multiple myeloma.
Myelogenous or myeloid: a malignancy in the myeloid lineage that includes precursor cells to red blood cells, platelets and white blood cells. Examples include acute myelogenous leukemia, chronic myeloid leukemia and myelodysplastic syndromes.
The classification also includes how quickly the disease develops and worsens (acute versus chronic).

 For example, there are 4 major types of leukemia:

  • Acute Lymphocytic leukemia
  • Chronic Lymphocytic leukemia
  • Acute Myeloid Leukemia
  • Chronic Myeloid Leukemia

What is the worldwide estimated incidence and mortality (2012) ?

    Incidence (% all cancers)         Mortality (% all cancers)
Leukemia 351 965 (2.5%) 265 471 (3.2%)
Hodgkin’s Lymphoma 65 950 (0.5%) 25 469 (0.3%)
Non-Hodgkin’s Lymphoma 385 741 (2.7%) 199 670 (2.4%)
Multiple Myeloma 114 251 (0.8%) 80 019 (1.0%)

Source – globocan.iarc.fr / 2012

These diseases are increasingly found in patients aged 65 and over. The survival of these conditions including those deemed incurable and the quality of life of people with the disease have been improved in recent years.

Partnering with MaaT Pharma
to accelerate the access of our drugs to patients.

We are constantly looking to explore new frontiers, improve our drugs and improve the preparation of our clinical trials. Therefore, we are open to partnerships with investigator-initiated studies to collect Big Data using our GutPrint® meta genomics platform.